Industry Update: Interim 503A and 503B Bulks Lists New Revisions The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Peptides: Legal and Regulatory Risks 503A Compounding Pharmacies Must Understand FDA Peptide Reclassification 2026: What It Means for Providers The Human Lab Rats Injecting Themselves with Peptides Office for Science and Society McGill University Best Way to Take BPC 157: Dosage & Administration